8.700
-0.290
(-3.23%)
As of 10:38:42 AM GMT+8. Market Open.
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
800,575
716,912
533,881
354,555
253,542
Cost of Revenue
224,412
210,878
142,131
107,115
86,549
Gross Profit
576,163
506,034
391,750
247,440
166,993
Operating Expense
723,993
812,102
997,751
776,005
547,252
Operating Income
-147,830
-306,068
-606,001
-528,565
-380,259
Net Non Operating Interest Income Expense
-97,806
-89,686
-53,972
-26,919
-16,788
Pretax Income
-237,844
-380,156
-601,353
-545,643
-476,691
Tax Provision
5,972
2,796
804
--
--
Net Income Common Stockholders
-243,816
-382,951
-601,945
-545,576
-428,091
Diluted NI Available to Com Stockholders
-243,816
-382,951
-601,945
-545,576
-428,091
Basic EPS
-0.61
-0.96
-1.58
-1.38
-1.08
Diluted EPS
-0.61
-0.96
-1.58
-1.38
-1.08
Basic Average Shares
398,258
398,314
381,004
396,688.420
396,688.420
Diluted Average Shares
398,258
398,314
381,004
396,688.420
396,688.420
Total Operating Income as Reported
-117,807
-270,285
-530,444
-505,816
-358,426
Rent Expense Supplemental
--
--
--
3,234
2,171
Total Expenses
948,405
1,022,980
1,139,882
883,120
633,801
Net Income from Continuing & Discontinued Operation
-243,816
-382,951
-601,945
-545,576
-428,091
Normalized Income
-252,364.500
-388,096
-636,537.250
-557,907
-354,960
Interest Income
8,102
10,158
2,167
12,506
5,749
Interest Expense
105,908
99,844
56,139
39,425
22,537
Net Interest Income
-97,806
-89,686
-53,972
-26,919
-16,788
EBIT
-131,936
-280,312
-545,214
-506,218
-454,154
EBITDA
-131,936
-97,867
-371,115
-378,121
-410,787
Reconciled Cost of Revenue
224,412
210,878
142,131
107,115
86,549
Reconciled Depreciation
--
182,445
174,099
128,097
43,367
Net Income from Continuing Operation Net Minority Interest
-243,816
-382,951
-601,945
-545,576
-428,091
Total Unusual Items Excluding Goodwill
11,398
6,860
46,123
12,331
-73,131
Total Unusual Items
11,398
6,860
46,123
12,331
-73,131
Normalized EBITDA
-143,334
-104,727
-417,238
-390,452
-337,656
Tax Rate for Calcs
0
0
0
--
--
Tax Effect of Unusual Items
2,849.500
1,715
11,530.750
--
--
12/31/2020 - 9/1/2022
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
9995.HK RemeGen Co., Ltd.
17.080
-2.95%
6990.HK Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
230.200
-1.88%
688578.SS Shanghai Allist Pharmaceuticals Co., Ltd.
78.47
-0.01%
1952.HK Everest Medicines Limited
47.550
-1.55%
SHJBF Shanghai Junshi Biosciences Co., Ltd.
1.9700
0.00%
ONTl.XC
2509.HK Qyuns Therapeutics Co., Ltd.
6.800
+7.94%
1877.HK JUNSHI BIO
14.640
+1.39%
1875.HK TOT BIOPHARM-B
1.810
+0.56%
6821.HK Asymchem Laboratories (Tianjin) Co., Ltd.
54.950
-0.36%